Barinthus Biotherapeutics merger closes, shareholders receive 0.111 Topco shares per share
BRNS•ADS agreement terminated and options converted
The ADS deposit agreement dated April 29, 2021, with Bank of New York Mellon was terminated upon effectiveness.
Outstanding equity options were converted into Topco options on substantially the same vesting and exercise terms.
Topco completes acquisition of Barinthus Biotherapeutics
Topco completed its acquisition of Barinthus Biotherapeutics, taking all issued and to-be-issued ordinary shares at the scheme effective time.
Each Barinthus share, including those underlying ADSs, was exchanged for 0.111 shares of Topco common stock.
Fractional share entitlements will be cashed out under the scheme and merger agreement terms.
